Author

Giuseppe Cianciolo

h-index 2 View on Semantic Scholar

We have 3 of 22 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Case report Open access Sep 2026

Case Report: Reopening the anabolic window — romosozumab added to ongoing denosumab for severe osteoporosis in two kidney transplant recipients

Kidney transplant recipients develop disorders of mineral and bone metabolism that further impair bone strength, leading to osteoporosis and a high fracture risk. However, evidence in this setting is limited. Romosozumab, a sclerostin inhibitor with both anabolic and antiresorptive effects, is an attractive option, but...

Simona Barbuto, Paolo Mastromauro, G. Zavatta et al. · Frontiers in Endocrinology · 0 citations

Open access Aug 2026

Longitudinal changes in cardiorenal risk scores after SGLT2 inhibitor initiation in patients with CKD with and without type 2 diabetes.

BACKGROUND Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have become the standard of care in managing chronic kidney disease (CKD) and heart failure (HF), both in patients with and without type 2 diabetes mellitus (T2DM). Nonetheless, identifying those at persistent high cardiovascular (CV) and renal risk remains...

I. Capelli, D. Vetrano, D. Ribichini et al. · JN. Journal of Nephrology (M... · 0 citations

Open access Jul 2026

Unsolved Issues in Managing CKD-Associated Osteoporosis: Myths, Facts, and Clinical Grey Zones.

Therapeutic management becomes increasingly complex in advanced CKD, where fracture risk is high, and evidence for osteoporosis treatments is limited, and evidence for osteoporosis treatments is limited.

Giuseppe Cianciolo, Antonio Bellasi, Sandro Giannini et al. · Kidney360 · 0 citations